Alpha 2.0
Login Register
» Authors » Jennifer Deese

Jennifer Deese

Explore the profile of Jennifer Deese including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 1510
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Reproductive Medicine
Top 10 Co-Authors
Lut Van Damme
Khatija Ahmed
Tania Crucitti
Kavita Nanda
Charles Morrison
Meng Wang
Irith De Baetselier
Lindi Masson
Thesla Palanee-Phillips
Pai Lien Chen
Published In
Sex Transm Infect
J Acquir Immune Defic Syndr
N Engl J Med
Contraception
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Systematic Literature Review of Maternal Antibodies in Human Milk Following Vaccination During Pregnancy or Lactation: Tetanus, Pertussis, Influenza and COVID-19
Deese J, Schaible K, Massierer D, Tingir N, Fell D, Atwell J
Pediatr Infect Dis J . 2025 Feb; 44(2S):S38-S42. PMID: 39951072
Background: Human milk (HM) contributes to infant disease protection through transfer of numerous bioactive molecules, including antibodies, though the mechanisms that determine HM antibody transfer and disease prevention in the...
2.
True and False Positive HIV Point of Care Test Results in a Prospective Multinational Study of At-Risk African Women: Implications for Large-Scale Repeat HIV Testing in HIV Prevention Programs
Morrison S, Batting J, Wanga V, Beesham I, Deese J, Hofmeyr G, et al.
J Acquir Immune Defic Syndr . 2024 Aug; 97(4):364-370. PMID: 39085989
Background: Accurate HIV point of care testing is the cornerstone of prevention and treatment efforts globally, although false (both negative and positive) results are expected to occur. Setting: We assessed...
3.
Prevalence and incidence of sexually transmitted infections among South African women initiating injectable and long-acting contraceptives
Harryparsad R, Meyer B, Taku O, Serrano M, Chen P, Gao X, et al.
PLoS One . 2023 Nov; 18(11):e0294285. PMID: 37948399
Background: South Africa is among the countries with the highest prevalence of sexually transmitted infections (STIs), including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). In 2017, there were an estimated...
4.
Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial
Deese J, Chen P, Gao X, Heffron R, Hobbs M, Lapple D, et al.
AIDS Behav . 2022 Nov; 27(3):978-983. PMID: 36357806
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial found no substantial difference in HIV acquisition risk between women randomised to injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper intrauterine...
5.
Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results
Taylor D, Deese J, Bahamondes L, Brache V, Veiga Jr N, Fuchs R, et al.
Contracept X . 2022 Aug; 4:100080. PMID: 35965654
Objective: To characterize return to ovulation after injecting Sayana Press (104 mg/0.65 mL medroxyprogesterone acetate [MPA] in the Uniject device) every 4 months for 1 year of treatment. Study Design:...
6.
Acceptability of the contraceptive Sayana® Press when injected every four months: Results from a twelve-month trial in Brazil, Chile and the Dominican Republic
Burke H, Packer C, Fuchs R, Brache V, Bahamondes L, Salinas A, et al.
Contraception . 2022 Apr; 113:95-100. PMID: 35483431
Objective: We assessed the acceptability of subcutaneous depot-medroxyprogesterone acetate 104 mg (Sayana® Press) when injected every 4 months for 12 months. Study Design: We assessed acceptability using questionnaires within a...
7.
Genital inflammatory status and the innate immune response to contraceptive initiation
Radzey N, Harryparsad R, Meyer B, Chen P, Gao X, Morrison C, et al.
Am J Reprod Immunol . 2022 Apr; 88(2):e13542. PMID: 35394678
Problem: Data on the effects of contraceptives on female genital tract (FGT) immune mediators are inconsistent, possibly in part due to pre-existing conditions that influence immune mediator changes in response...
8.
Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial
Deese J, Brache V, Bahamondes L, Salinas A, Jorge A, Veiga Jr N, et al.
EClinicalMedicine . 2022 Feb; 44:101273. PMID: 35128365
Background: Sayana Press® is a 3-monthly contraceptive injection approved by regulatory agencies in more than 40 countries worldwide. Existing effectiveness and pharmacokinetics (PK) data suggest that high contraceptive efficacy may...
9.
Recent Advances and New Challenges in Cisgender Women's Gynecologic and Obstetric Health in the Context of HIV
Deese J, Heffron R, Jaspan H, Masson L, Smit J, Sibeko S
Clin Obstet Gynecol . 2021 Jul; 64(3):475-490. PMID: 34323229
Although rates of human immunodeficiency virus (HIV) have declined globally over the past 10 years, United Nations Programme on HIV/AIDS estimates 1.7 million new infections occurred in 2019, with cisgender...
10.
ART initiation among women newly diagnosed with HIV in a contraceptive trial in sub-Saharan Africa
Beesham I, Issema R, Palanee-Phillips T, Onono M, Evans S, Beksinska M, et al.
AIDS Care . 2021 Jun; 34(4):478-485. PMID: 34180277
Current guidelines recommend starting antiretroviral therapy (ART) as soon as possible after HIV diagnosis to reduce morbidity, mortality and onward HIV transmission. We examined factors influencing ART initiation by women...